Major R&D Projects:
-
Development of peroxynitrite scavengers (nitroscience™)
-
Development of matrix metalloproteinase (MMP) inhibitors (MMPharma™ Project, see www.mmpharma.com)
- Development of activators of biglycan activity (biglycan™)
Major R&D Grants:
Development of drug candidates based on genomics and chemoinformatics against myocardial infarction:
inhibitors of matrix metalloproteinases. For further information www.mmpharma.com
Jedlik Anyos Grant (NKFP_06_A1_MMP_2006, awarded for the period of 2007-2010)
Platform of mouse and human embryonic stem cell-derived cardiomyocyte test systems for drug development
Jedlik Anyos Grant (ESZHEART, awarded for the period of 2008-2010)
Modulation of peroxynitrite-induced myocardial damage by pharmacological and gene therapies,
and development of clinical applications of peroxynitrite markers.
(GVOP-331-2004-04-0095_30, awarded for the period of 2005-2007)
Recent Publications of PharmaHungary™:
Kocsis GF, Pipis J, Fekete V, Kovacs-Simon A, Odendaal L, Molnar E, Giricz Z, Janaky T, van Rooyen J, Csont T, Ferdinandy P. Lovastatin interferes with the infarct size-limiting effect of ischemic preconditioning and postconditioning in rat hearts. Am J Physiol Heart Circ Physiol 2008 Mar 21; [Epub ahead of print]
Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning and postconditioning. Pharmacol Rev 59:418-458 (2007)
Dormán G, Kocsis-Szommer K, Spadoni C, Ferdinandy P. MMP inhibitors in cardiac diseases: an update.
Recent Patents Cardiovasc Drug Discov 2:186-194 (2007).
Csont T, Bereczki E, Bencsik P, Fodor G, Gorbe A, Zvara A, Csonka C, Puskas LG, Santha M, Ferdinandy P.
Hypercholesterolemia increases myocardial oxidative and nitrosative stress thereby leading to cardiac dysfunction in apoB-100 transgenic mice.
Cardiovasc Res. 76:100-109 (2007)
Papp A, Szommer T, Barna L, Gyimesi G, Ferdinandy P, Spadoni C, Darvas F, Fujita T, Ürge L, Dormán G. Enhanced hit-to-lead process using bioanalogous lead evolution and chemogenomics: application in designing selective matrix metalloprotease inhibitors. Expert Opin Drug Discov 2:707-723 (2007)
Bereczki E, Gonda S, Csont T, Korpos E, Zvara A, Ferdinandy P, Santha M. Overexpression of biglycan
in the heart of transgenic mice: an antibody microarray study.
J Proteome Res. 6:854-861(2007)
Ferdinandy P. Peroxynitrite: just an oxidative/nitrosative stressor or a physiological regulator as well?
Br J Pharmacol 148:1-3 (2006).
Turan N, Csonka C, Csont T, Giricz Z, Fodor G, Bencsik P, Gyongyosi M, Cakici I, Ferdinandy P.
The role of peroxynitrite in chemical preconditioning with 3-nitropropionic acid in rat hearts.
Cardiovasc Res 70:384-390 (2006)
Konya C, Ferdinandy P. Vitamin C: new role of the old vitamin in
the cardiovascular system.
Br J Pharmacol 147:125-127 (2006)
Giricz Z, Lalu MM, Csonka C, Bencsik P, Schulz R, Ferdinandy P. Hyperlipidemia attenuates the infarct
size-limiting effect of ischemic preconditioning: role of matrix metalloproteinase-2 inhibition.
J Pharmacol Exp Ther 316:154-61(2006)
Ungi I, Ungi T, Ruzsa Z, Nagy E, Zimmermann Z, Csont T, Ferdinandy P. Hypercholesterolemia attenuates
the anti-ischemic effect of preconditioning during coronary angioplasty. Chest 128:1623-1628 (2005)
Br J Pharmacol 147:125-127 (2006)
Giricz Z, Lalu MM, Csonka C, Bencsik P, Schulz R, Ferdinandy P. Hyperlipidemia attenuates the infarct
size-limiting effect of ischemic preconditioning: role of matrix metalloproteinase-2 inhibition.
J Pharmacol Exp Ther 316:154-61(2006)
Ungi I, Ungi T, Ruzsa Z, Nagy E, Zimmermann Z, Csont T, Ferdinandy P. Hypercholesterolemia attenuates
the anti-ischemic effect of preconditioning during coronary angioplasty. Chest 128:1623-1628 (2005)